New hope for Hard-to-Treat lung cancer: targeted drug combo shows promise
NCT ID NCT07392658
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of the targeted drug amivantamab plus chemotherapy (pemetrexed or gemcitabine) in 33 people with advanced non-small cell lung cancer that has a specific EGFR exon20 insertion mutation. Participants have not had prior treatment and are not healthy enough for standard platinum-based chemotherapy. The study aims to see if the combination shrinks tumors and improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
amivantamab (a targeted cancer drug) plus either pemetrexed or gemcitabine (chemotherapy)
What this could lead to
If successful, this could offer a new treatment option for people with a specific type of advanced lung cancer who cannot tolerate standard platinum chemotherapy.
What could go wrong
This is a small, early-phase trial (33 people) with no control group, so results may not be definitive. Side effects from the drug combination could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
I.F.O. Istituti Fisioterapici Ospitalieri Istituto Nazionale Tumori "Regina Elena", Medical Oncology 2
RECRUITINGRoma, Roma (RM), 00144, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••